To explore whether GEMINI could be used to monitor patients during therapy, we assessed serial blood samples from patients with lung cancer who were undergoing treatment with EGFR or ERBB2 inhibitors with mutant allele fractions (MAFs) as low as 0.1% (Supplementary Table 5). This evidence concerns the gene ERBB2 and lung carcinoma.